Market Overview - The Shanghai Composite Index increased by 0.11% as of the morning close, with a trading volume of 661.79 million shares and a total transaction value of 808.39 billion yuan, a decrease of 3.50% compared to the previous trading day [1]. Industry Performance - The banking sector showed the highest increase at 1.04%, with a transaction value of 208.46 billion yuan, up by 24.88% from the previous day, led by Minsheng Bank which rose by 3.70% [1]. - The pharmaceutical and biological industry followed with a 0.79% increase, totaling 900.02 billion yuan in transactions, down by 6.28%, with Sai Sheng Pharmaceutical leading at 20.00% [1]. - The oil and petrochemical sector rose by 0.71%, with a transaction value of 48.56 billion yuan, down by 10.44%, led by Yueyang Xingchang which increased by 3.46% [1]. Declining Industries - The defense and military industry experienced the largest decline at 1.52%, with a transaction value of 303.33 billion yuan, down by 19.95%, led by Jieqiang Equipment which fell by 13.63% [2]. - The computer industry decreased by 1.34%, with a transaction value of 745.93 billion yuan, down by 3.28%, led by the delisted Longyu which dropped by 39.84% [2]. - The telecommunications sector saw a decline of 0.87%, with a transaction value of 392.96 billion yuan, down by 20.67%, led by the delisted Pengbo which fell by 59.68% [2].

Group 1 - The innovative drug concept stocks are experiencing a downturn, with several companies seeing declines of over 5% [1] - Notable companies affected include Sanofi, Haisun Pharmaceutical, Huisheng Biological, Rejing Biological, Haichuang Pharmaceutical, and Ruizhi Pharmaceutical [1] - Other companies such as Saiseng Pharmaceutical and Hasan Union are also following the downward trend [1]

Group 1 - The recombinant protein concept sector rose by 2.52%, ranking second among concept sectors, with 30 stocks increasing in value [1][2] - Notable gainers included Sangon Biotech, which hit the daily limit with a 20% increase, and other significant performers such as Sai Sheng Pharmaceutical, Jie Ya Co., and Jinbo Bio, which rose by 16.37%, 9.31%, and 9.17% respectively [1][2] - The sector experienced a net inflow of 221 million yuan from main funds, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Leading the net inflow was Xilong Scientific, which saw a net inflow of 242 million yuan, followed by Rejuve Pharmaceutical and Zexin Pharmaceutical with net inflows of 37.78 million yuan and 32.48 million yuan respectively [2][3] - The top three stocks by net inflow ratio were Xilong Scientific at 20.85%, Zexin Pharmaceutical at 8.53%, and Chengdu Xian Dao at 7.96% [3][4] - Stocks with notable declines included Furuida, Zhongyuan Xiehe, and Wanmei Biological, which fell by 2.25%, 1.92%, and 1.80% respectively [1][5]

Market Performance - Major stock indices in China saw significant gains, with the North China 50 Index rising over 1% to reach a new high [1] - The FTSE China A50 Index futures increased by more than 1%, while the offshore RMB appreciated by 101 points against the USD, currently at 7.2041 [2] - The Shanghai Composite Index closed up 0.38% at 3393.49 points, with the Shenzhen Component Index up 0.53% and the ChiNext Index up 0.99% [2] Sector Highlights - The coal sector showed strong performance, with companies like Dayou Energy and Jinkong Coal Industry hitting the daily limit, and Shanmei International rising nearly 6% [2] - The solid-state battery concept gained traction, with companies like Lingpai Technology and Ningde Times seeing significant price increases, with Lingpai Technology hitting a 20% limit up [2][4] - The innovative drug sector remained active, with Shuyitai and SanSheng Guojian both hitting the daily limit, and SaiSheng Pharmaceutical rising over 12% [7] Company Developments - Ningde Times, which recently listed on the Hong Kong Stock Exchange, saw its stock rise by over 9% during trading [3] - Bubble Mart reached a new historical high, with its stock price rising over 5% to 220 HKD per share, bringing its market capitalization close to 300 billion HKD [10] - Bubble Mart's Labubu 3.0 product has gained immense popularity globally, leading to long queues in stores and significant price premiums on secondary markets [12] Industry Trends - The solid-state battery sector is identified as a core focus within the lithium battery industry, with companies actively launching new products and materials seeing increased demand [6] - The innovative drug market in China is projected to grow from 132.5 billion USD in 2019 to 159.2 billion USD by 2024, maintaining a global market share of around 15% [9]

证券代码：300485 证券简称：赛升药业 公告编号：2025-020 北京赛升药业股份有限公司 一、会议召开情况 表决结果：赞成 8 票、反对 0 票、弃权 0 票、回避 0 票。 第五届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第七次会议 于2025年4月22日在公司会议室召开，本次会议于2025年4月18日以通讯的方式向 所有董事送达了会议通知。会议应参会董事8人，实际参会董事8人，会议由董事 长马骉先生主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符 合《中华人民共和国公司法》（以下简称"《公司法》"）等有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 审议通过《关于公司〈2025年第一季度报告〉的议案》 经审核，全体董事一致认为，公司《2025 年第一季度报告》符合中国证监 会、深圳证券交易所有关季度报告的编制规范，报告内容真实、准确、完整地反 映了公 ...

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 7725.04万股，累计占流通股比： 28.22%，较上期变化： -181.42万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | 马骉 | 5961.60 | 21.77 | 不变 | | 马丽 | 746.17 | 2.73 | 不变 | | 刘淑芹 | 218.70 | 0.80 | 不变 | | 中国民生银行股份有限公司-金元顺安元启灵活配置混合 | | | | | 型证券投资基金 | 136.00 | 0.50 | 新进 | | 赵竞东 | 120.00 | 0.44 | 不变 | | 香港中央结算有限公司 | 117.21 | 0.43 | -182.89 | | 高盛公司有限责任公司 | 114.21 | 0.42 | 新进 | | MORGAN STANLEY & CO. INTERNATIONAL PLC. | 105.18 | 0.38 | 新进 | | 李彤 | 104.70 ...

Financial Performance - The company's revenue for Q1 2025 was ¥92,536,534.42, a decrease of 15.52% compared to ¥109,535,330.56 in the same period last year[4] - Net profit attributable to shareholders was ¥39,970,025.94, representing a significant increase of 120.97% from a loss of ¥190,617,604.88 in the previous year[4] - Basic and diluted earnings per share were both ¥0.0830, up 120.98% from a loss of ¥0.3957 per share in the previous year[4] - The company's total profit for the quarter was ¥47,504,454.06, a 121.11% increase from a loss of ¥225,040,253.45 in the same period last year[8] - The total comprehensive income for the first quarter of 2025 was CNY 38,892,408.64, a 120.23% increase compared to the same period in 2024[9] - The net profit attributable to the parent company reached CNY 39,917,502.64, reflecting a 120.95% increase year-over-year[9] - The company reported a net profit of ¥38,944,931.94, compared to a net loss of ¥192,345,921.24 in the previous period, indicating a significant turnaround in performance[20] - Operating profit was ¥47,375,395.14, while the previous period showed an operating loss of ¥225,039,153.45, reflecting improved operational efficiency[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 74.63% to ¥10,683,764.62 from ¥42,114,786.47 in the same period last year[4] - Cash and cash equivalents decreased by 52.99% to CNY 59,346,661.92 from CNY 126,240,055.05 at the end of the previous year[9] - The company reported a 92.49% decrease in cash received from operating activities, totaling CNY 102,289.85, primarily due to the absence of government subsidies received in the previous year[9] - Operating cash flow for the first quarter was CNY 99,495,887.84, up 38.21% from CNY 71,989,356.62 in the same period last year[9] - The company recorded cash inflows from investment activities of ¥471,008,667.12, significantly higher than ¥164,833,714.82 in the previous period, indicating aggressive investment strategies[22] - The net cash flow from investment activities was -¥26,563,589.71, an improvement from -¥36,081,201.81 in the previous period, suggesting better management of investment cash flows[22] Assets and Liabilities - Total assets increased by 1.03% to ¥3,588,460,056.06 from ¥3,551,848,565.47 at the end of the previous year[4] - Current assets totaled ¥1,737,109,249.51, up from ¥1,711,643,897.26, reflecting an increase of 1.5%[16] - Non-current assets rose to ¥1,851,350,806.55 from ¥1,840,204,668.21, showing an increase of 0.8%[16] - Total liabilities decreased to ¥164,200,091.96 from ¥166,481,010.01, a decline of 1.4%[16] - The company's retained earnings increased to ¥1,823,350,235.01 from ¥1,783,380,209.07, an increase of 2.2%[17] - The total equity attributable to shareholders rose to ¥3,397,029,455.23 from ¥3,357,111,952.59, reflecting an increase of 1.2%[17] Expenses - The company reported a significant decrease in sales expenses by 30.89% to ¥29,937,487.70 from ¥43,319,060.18 in the previous year, primarily due to reduced marketing costs[8] - Total operating costs decreased to ¥90,214,129.14 from ¥103,930,716.38, reflecting a reduction of 13.2%[19] - Research and development expenses increased to ¥11,888,734.88, up from ¥9,168,151.11, indicating a rise of 29.6%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,384[11] - The largest shareholder, Ma Xie, holds 49.51% of the shares, totaling 238,464,000 shares[11] Other Information - The company did not report any significant new product launches or technological advancements during this period[20]

证券代码:300485 证券简称：赛升药业 公告编号：2025-018 北京赛升药业股份有限公司 关于子公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 特此公告。 北京赛升药业股份有限公司 董 事 会 北京赛升药业股份有限公司（以下简称"公司"）子公司北京赛而生物药业 有限公司（以下简称"赛而生物"）近日获得了北京市药品监督管理局颁发的《药 品生产许可证》。本次涉及变更的事项为：经审查，同意企业负责人名称由"马 骉"变更为"郑计"；其他内容未做变更。 一、《药品生产许可证》的基本信息 企业名称：北京赛而生物药业有限公司 许可证编号：京 20150048 社会信用代码：91110115742602836G 分类码：AhzChDhz 注册地址：北京市大兴区工业开发区科苑路 35 号 法定代表人：马骉 企业负责人：郑计 质量负责人：郑计 有效期至：2025 年 12 月 07 日 生产地址和生产范围： 北京市大兴区工业开发区科苑路 35 号：片剂（含头孢菌素类）、硬胶囊剂 （含头孢菌素类）、颗粒剂、散剂*** 蓟州区京津州河科技产业园腾 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达律师事务所 关于北京赛升药业股份有限公司 2024 年年度股东大会的法律意见书 康达股会字【2025】第 0097 号 致：北京赛升药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东 会规则》（以下简称"《规则》"）、《深圳证券交易所上市公司股东大会网络投票 实施细则》（以下简称"《实施细则》"）、《北京赛升药业股份有限公司章程》（以 下简称"《公司章程》"）及北京赛升药业股份有限公司（以下简称"公司"）与北 京市 ...

证券代码:300485 证券简称：赛升药业 公告编号：2025-019 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更议案的情形。 2、本次股东大会不涉及变更前次股东大会决议的情形。 3、本次股东大会采取现场投票与网络投票相结合的表决方式。 一、会议召开和出席情况 会议召开情况： 1、会议召集人：公司董事会 2、会议方式：本次会议采取现场投票和网络投票相结合的方式 北京赛升药业股份有限公司 2024 年年度股东大会决议公告 3、会议召开时间： （1）现场会议召开时间为：2025 年 4 月 21 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 4 月 21 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过互联网投 票系统投票的具体时间为：2025 年 4 月 21 日 9:15-15:00 任意时间。 4、会议地点：北京市北京经济技术开发区兴盛街 8 号 5、会议主持人：董事长马骉先生 6、本次会议的召集、召开符合《公司法》《上市 ...